We came across a bullish thesis on Recursion Pharmaceuticals, Inc. on r/stocks by Antique-Reference585. In this article, we ...

Recursion Pharmaceuticals has reported updated data from its ELUCIDATE & TUPELO trials, but the stock has failed to mount a ...

AI 制药上市公司 Recursion（NASDAQ: RXRX）宣布与英伟达（NVIDIA）建立了合作伙伴关系，并获得英伟达 5000 万美元的投资。 AI 制药上市公司 Recursion（NASDAQ: RXRX）宣布与英伟达（NVIDIA）建立了合作伙伴关系，并获得英伟达 5000 万美元的投资。 达成协议后，两家公司计划 ...

And its investments in AI could, eventually, lead to important monetization opportunities even beyond advertising, perhaps ...

Recursion和Exscientia plc今天宣布两家公司已达成最终协议，将Recursion和Exscientia合并，前者能够解码生物学以实现药物发现的工业化，后者致力于更快地为患者创造更有效的药物。 8月8日，盐湖城和英国牛津，Recursion（NASDAQ：RXRX）和Exscientia plc（NASDAQ：EXAI）今天宣布 ...

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is one of the best debt-free penny stocks to buy right now. On December 17, ...

Recursion Pharmaceuticals（纳斯达克股票代码：RXRX） 董事Christopher Gibson于2026年1月5日以每股4.25美元的价格出售了4万股A类普通股，总计17万美元。根据 InvestingPro 数据显示，该交易发生之际，该公司股票在过去一周内价格大幅上涨了18.83%，目前股价为4.86美元。

Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a ...

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13 ...

Wondering if Recursion Pharmaceuticals at around US$4.67 a share is priced for its potential or still misunderstood by the ...

Recursion Pharmaceuticals presents a compelling investment opportunity due to its AI-driven drug discovery platform, solid financials, and diverse pipeline, setting it apart from competitors like ...